Stock ASND ASCENDIS PHARMA A/S
Add to a list
To use this feature you must be a member
Log inSign up

Ascendis Pharma A/S Share Price

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
135.9 USD -0.75% Intraday chart for Ascendis Pharma A/S -3.05% +7.90%
26/04 European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% MT
25/04 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT

Financials

Sales 2024 * 425M 454M 37.87B Sales 2025 * 742M 794M 66.2B Capitalization 7.27B 7.78B 649B
Net income 2024 * -236M -252M -21.05B Net income 2025 * 10M 10.69M 892M EV / Sales 2024 * 18 x
Net Debt 2024 * 390M 416M 34.74B Net Debt 2025 * 323M 345M 28.78B EV / Sales 2025 * 10.2 x
P/E ratio 2024 *
-29.7 x
P/E ratio 2025 *
3,042 x
Employees 879
Yield 2024 *
-
Yield 2025 *
-
Free-Float 10.4%
More Fundamentals * Assessed data

Chart Ascendis Pharma A/S

Dynamic Chart

Latest news about Ascendis Pharma A/S

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism MT
Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
JPMorgan Adjusts Ascendis Pharma A/S Price Target to $167 From $165, Maintains Overweight Rating MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
Wells Fargo Raises Ascendis Pharma Price Target to $260 From $196, Maintains Overweight Rating MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading MT
Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer CI
European Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday Trading MT
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading MT
More news

Latest transcript on Ascendis Pharma A/S

Logo Ascendis Pharma A/S
Ascendis Pharma A/S, 2023 Earnings Call, Feb 07, 2024
More transcripts

Analyst Recommendations on Ascendis Pharma A/S

JPMorgan Adjusts Ascendis Pharma A/S Price Target to $167 From $165, Maintains Overweight Rating MT
Wells Fargo Raises Ascendis Pharma Price Target to $260 From $196, Maintains Overweight Rating MT
Citigroup Raises Price Target on Ascendis Pharma to $182 From $146, Maintains Buy Rating MT
Wedbush Raises Ascendis Pharma's Pt to $225 From $207, Notes Multiple Catalysts Across Pipeline in Q4 2024; Keeps Outperform Rating MT
Cantor Fitzgerald Adjusts Price Target on Ascendis Pharma to $173 From $152, Keeps Overweight Rating MT
More recommendations

Press releases Ascendis Pharma A/S

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024 AQ
Ascendis Pharma - United Kingdom's MHRA Approves YORVIPATH in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism AQ
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism AQ
Ascendis Pharma A/S : Form 6-K PU
Ascendis Pharma A/S : Form 6-K PU
More press releases

News in other languages on Ascendis Pharma A/S

EN DIRECT DES MARCHES : Kering, Renault, L'Oréal, Casino, Cellectis, Boeing, Roche...
Fin des poisons d'avril ?
More news

Quotes and Performance

1 day-0.75%
1 week-3.05%
Current month-10.10%
1 month-9.38%
3 months+2.60%
6 months+52.70%
Current year+7.90%
More quotes

Highs and lows

1 week
133.39
Extreme 133.39
147.45
1 month
133.39
Extreme 133.39
156.84
Current year
119.03
Extreme 119.03
161.00
1 year
66.03
Extreme 66.03
161.00
3 years
61.58
Extreme 61.5791
178.71
5 years
61.58
Extreme 61.5791
183.98
10 years
11.92
Extreme 11.92
183.98
More quotes

Managers and Directors - Ascendis Pharma A/S

Managers TitleAgeSince
Jan Mikkelsen FOU
 Founder 65 01/06/01
Scott Smith DFI
 Director of Finance/CFO 50 08/16/08
Stina Singel CTO
 Chief Tech/Sci/R&D Officer 50 01/20/01
Members of the board TitleAgeSince
Jan Mikkelsen FOU
 Founder 65 01/06/01
Albert Cha CHM
 Chairman 51 01/14/01
Michael Wolff Jensen LAW
 General Counsel 53 01/08/01
More insiders

ETFs positioned on Ascendis Pharma A/S

Name Weight AuM 1st Jan change Investor Rating
ADVISORSHARES ALPHA DNA EQUITY SENTIMENT ETF - USD ETF AdvisorShares Alpha DNA Equity Sentiment ETF - USD
0.96% 11 M€ -6.03% -
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
0.48% 0 M€ 0.00% -
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
0.45% 0 M€ 0.00% -
More ETFs positioned on Ascendis Pharma A/S

Quotes

Date Price Change Volume
26/24/26 135.9 -0.75% 226,133
25/24/25 136.9 -4.37% 376,771
24/24/24 143.2 -1.14% 244,224
23/24/23 144.8 +1.92% 220,120
22/24/22 142.1 +1.38% 245,698

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes

Company Profile

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Sector
Biotechnology & Medical Research
Calendar
03/05/2024 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Ascendis Pharma A/S

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
127.3 EUR
Average target price
166.7 EUR
Spread / Average Target
+30.97%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ASCENDIS PHARMA A/S Stock Ascendis Pharma A/S
+7.90% 7.76B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ASND Stock